Skip to main content

Table 6 Relative contribution of 223Ra and its progeny to the total absorbed dose of endosteum, red marrow, liver and kidneys (in %)

From: Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

  223Ra 219Rn 215Po 211Pb 211Bi 211Po 207TI
Tissue        
Red marrow 19 24 26 4 22 0 4
Endost-BS 21 25 27 1 24 0 1
Liver 21 24 27 2 24 0 2
Kidneys 20 24 26 2 26 0 2
  1. Endost-BS, endosteum (endosteal cells)